Investors Invited to Take Charge in Aquestive Therapeutics Securities Fraud Case Rosen Law Firm announces that investors in Aquestive Therapeutics may take part in a significant securities fraud lawsuit with a deadline approaching.

Investors Invited to Take Charge in Aquestive Therapeutics Securities Fraud Case #USA #New_York #Securities_Fraud #Rosen_Law_Firm #AQST

Aquestive gets FDA feedback on oral epinephrine film for severe allergies Preliminary FDA comments covered study design and packaging changes, as the company targets human-factor and PK work before final meeting minutes in May.

#AQST Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

www.stocktitan.net/news/AQST/aquestive-ther...

Faruqi & Faruqi Alerts Investors of Deadline for This Securities Class Action Against Aquestive Therapeutics Faruqi & Faruqi, LLP is reminding investors in Aquestive Therapeutics of the impending class action deadline of May 4, 2026, regarding their securities.

Faruqi & Faruqi Alerts Investors of Deadline for This Securities Class Action Against Aquestive Therapeutics #USA #New_York #Faruqi_&_Faruqi #Aquestive_Therapeutics #AQST

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ESTC, #OLPX, #MARA, #MLCO, #AQST

#OptionFlow #OptionsTrading #Trading

Shareholders of Aquestive Therapeutics Urged to Join Class Action Lawsuit Amid Allegations Investors in Aquestive Therapeutics are encouraged to join a class action lawsuit following significant stock price decline due to misleading statements about their drug. Don't miss your chance to participate.

Shareholders of Aquestive Therapeutics Urged to Join Class Action Lawsuit Amid Allegations #USA #New_York #Gross_Law_Firm #Aquestive_Therapeutics #AQST

Investors Beware: Important Deadline for Aquestive Therapeutics Securities Class Action Looms Faruqi & Faruqi, LLP reminds investors of the looming deadline for the securities class action against Aquestive Therapeutics. Act by May 4, 2026.

Investors Beware: Important Deadline for Aquestive Therapeutics Securities Class Action Looms #United_States #New_York #Faruqi_Law #Aquestive_Therapeutics #AQST

Investors Urged to Take Action Following Significant Price Target Cut for Aquestive Therapeutics Following a drastic reduction in price target for Aquestive Therapeutics by Cantor, investors face substantial losses and potential class action opportunities.

Investors Urged to Take Action Following Significant Price Target Cut for Aquestive Therapeutics #United_States #New_York #Class_Action #Aquestive_Therapeutics #AQST

Important Security Class Action Reminder for Aquestive Therapeutics Investors: Deadline Approaching Faruqi & Faruqi, LLP warns Aquestive Therapeutics investors about the approaching deadline for a securities class action. Don’t miss out on your rights.

Important Security Class Action Reminder for Aquestive Therapeutics Investors: Deadline Approaching #USA #New_York #Faruqi_&_Faruqi #Aquestive_Therapeutics #AQST

Pomerantz Law Firm Urges Investors in Aquestive Therapeutics to Join Class Action Lawsuit Following Major Stock Drop Pomerantz Law Firm has filed a class action lawsuit against Aquestive Therapeutics, urging affected investors with losses to act before deadlines pass. Stay informed.

Pomerantz Law Firm Urges Investors in Aquestive Therapeutics to Join Class Action Lawsuit Following Major Stock Drop #United_States #New_York #Pomerantz_LLP #Aquestive_Therapeutics #AQST

Investor Turmoil: A Dismal Future for Aquestive Therapeutics After Price Target Slashing Aquestive Therapeutics faces a daunting challenge following a significant price target reduction by Cantor. Investors may suffer considerable losses as concerns mount over the company's future.

Investor Turmoil: A Dismal Future for Aquestive Therapeutics After Price Target Slashing #USA #New_York #Stock_Market #Aquestive_Therapeutics #AQST

AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt {"summary":"","positive":[],"negative":[],"faq":[]}

#AQST AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt

www.stocktitan.net/news/AQST/aqst-lawsuit-a...

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days On track to submit regulatory applications for Anaphylm in Canada and the EU in 2026 Extends revenue sharing agreement with RTW to June 30, 2027

#AQST Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/AQST/aquestive-ther...

Breaking News: ( NASDAQ: #AQST ) Aquestive Therapeutics Inc. (NASDAQ: AQST) Sees Notable Increase in Monday Morning Market Activity

📢 Stocks Trending NOW: #DIS #ORCL #ELPW #AQST #APP #U #DKI #BMNR #PHOE #VHUB

Faruqi & Faruqi Investigates Potential Claims Against Aquestive Therapeutics for Investors A leading law firm, Faruqi & Faruqi, is probing claims for investors of Aquestive Therapeutics following a significant stock decline caused by FDA concerns.

Faruqi & Faruqi Investigates Potential Claims Against Aquestive Therapeutics for Investors #USA #New_York #Faruqi_&_Faruqi #Aquestive_Therapeutics #AQST

Pomerantz Law Firm Probes Potential Fraud Claims Against Aquestive Therapeutics Investors Pomerantz LLP is looking into claims for investors of Aquestive Therapeutics, Inc. regarding possible securities fraud and business misconduct.

Pomerantz Law Firm Probes Potential Fraud Claims Against Aquestive Therapeutics Investors #USA #New_York #Securities_Fraud #Pomerantz_LLP #AQST

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update Aquestive Therapeutics (NASDAQ: AQST) said the FDA identified deficiencies in the Anaphylm (dibutepinephrine) NDA that currently preclude labeling discussions, while confirming the agency's review remains ongoing and no final decision has been made. The company said a Discipline Review Letter will not be issued but information requests are possible and delays in communicating deficiencies could delay approval before the PDUFA action date of Jan 31, 2026. The Anaphylm program includes 11 studies with ~967 administrations across 411 subjects. Aquestive reported ~$120 million cash as of Dec 31, 2025 and plans regulatory submissions in Canada, Europe, and the UK in 2026.

#AQST Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

www.stocktitan.net/news/AQST/aquestive-ther...

#AQST Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/AQST/aquestive-ther...

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ Aquestive Therapeutics (NASDAQ: AQST) announced the USPTO issued two new U.S. composition patents for Anaphylm (dibutepinephrine) Sublingual Film, extending patent protection through at least May 4, 2037. The patents (U.S. 12,427,121 and U.S. 12,443,850) cover epinephrine prodrug formulations and film-based oral mucosal absorption enabled by the company's PharmFilm and Adrenaverse technologies.Anaphylm is positioned as a device-free, oral sublingual alternative to injectable epinephrine for severe allergic reactions. The FDA PDUFA target action date for Anaphylm is January 31, 2026. Each patent expiration is subject to any applicable extensions.

#AQST Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

www.stocktitan.net/news/AQST/aquestive-ther...

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday - Robo.ai (NASDAQ:AIIO), Aquestive Therapeutics (NASDAQ:AQST) U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shar...

#AIIO #AQST #ASM #BB #big #gainers #CRNX #CRS #GRRR #Mid #Day

Origin | Interest | Match

Leading Indicators, Thursday September 4, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Thu Sept 4th - #BRIA #CIGL #BSLK #BBLG #SCVL #NKTR #DLTH #AQST #AEO - More: crystalequityresearch.com/leading-indi... - #smallcap

First-Ever Needle-Free Epinephrine Film: Aquestive's Anaphylm Clears Key FDA Hurdle Without Committee Review Aquestive's sublingual Anaphylm film for anaphylaxis treatment advances toward Jan 31, 2026 PDUFA date. Novel therapy tested in 967 doses across 11 clinical studies, backed by $160M financing.

#AQST Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

www.stocktitan.net/news/AQST/aquestive-ther...

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock Aquestive Therapeutics (NASDAQ: AQST) has announced the pricing of an underwritten public offering of 21,250,000 shares of common stock at $4.00 per share, expected to raise gross proceeds of $85 million.The offering, led by RTW Investments with participation from notable investors including Samsara BioCapital and EcoR1 Capital, is expected to close around August 15, 2025. The proceeds will primarily fund the launch and commercialization of Anaphylm™ Sublingual Film for severe allergic reactions, pending FDA approval.Leerink Partners, Cantor, and Oppenheimer & Co. are serving as joint bookrunning managers, with H.C. Wainwright as lead manager and Brookline Capital Markets as co-manager for the offering.

#AQST Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

www.stocktitan.net/news/AQST/aquestive-ther...

First-Ever Oral Emergency Allergy Treatment Gets $75M Boost from RTW Investment RTW Investments backs Aquestive's Anaphylm, a groundbreaking sublingual film for severe allergic reactions. Funding contingent on FDA approval. Learn launch timeline.

#AQST Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

www.stocktitan.net/news/AQST/aquestive-ther...

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Aquestive Therapeutics (NASDAQ:AQST) reported Q2 2025 financial results and significant progress with its lead product candidate Anaphylm™, an oral sublingual film for epinephrine delivery. The FDA accepted the NDA for Anaphylm with a PDUFA date of January 31, 2026. The company is preparing for a Q1 2026 U.S. launch while expanding globally to Canada and EU.Q2 2025 financial highlights include revenue of $10.0 million, up 3% year-over-year excluding one-time items, and a net loss of $13.5 million. Cash position stands at $60.5 million as of June 30, 2025. The company maintains its 2025 guidance with expected revenue of $44-50 million.The company is also advancing AQST-108, a topical gel treatment for alopecia areata, with IND submission planned for Q4 2025. Manufacturing operations remain stable with continued production of Suboxone® and other partnership products.

#AQST Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/AQST/aquestive-ther...

EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer Former EpiPen marketing leader joins Aquestive's C-suite to spearhead launch of first-ever oral epinephrine treatment. See launch strategy details.

#AQST Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

www.stocktitan.net/news/AQST/aquestive-ther...

Revolutionary Needle-Free Anaphylaxis Treatment Takes Major Step Toward Global Expansion Aquestive's oral epinephrine film progresses with Health Canada meeting and EMA submission. First-ever needle-free anaphylaxis treatment expanding globally. Learn timeline.

#AQST Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

www.stocktitan.net/news/AQST/aquestive-ther...

Revolutionary Needle-Free Epinephrine Treatment Advances: FDA Sets 2026 Decision Date for Oral Anaphylaxis Drug First-ever oral epinephrine treatment for anaphylaxis moves closer to approval. Credit-card thin, needle-free design could transform emergency allergy care. See timeline.

#AQST Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

www.stocktitan.net/news/AQST/aquestive-ther...